Comparing Individualized Survival Predictions From Random Survival Forests and Multistate Models in the Presence of Missing Data: A Case Study of Patients With Oropharyngeal Cancer

被引:0
|
作者
Abbott, Madeline R. [1 ]
Beesley, Lauren J. [1 ,2 ]
Bellile, Emily L. [1 ]
Shuman, Andrew G. [3 ]
Rozek, Laura S. [4 ]
Taylor, Jeremy M. G. [1 ]
机构
[1] Univ Michigan, Dept Biostat, 1415 Washington Hts, Ann Arbor, MI 48109 USA
[2] Los Alamos Natl Lab, Informat Syst & Modeling, Los Alamos, NM USA
[3] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA
[4] Georgetown Univ, Dept Oncol, Sch Med, Washington, DC USA
关键词
Survival analysis; multistate model; random survival forest; predictive accuracy; cancer application; missing data;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In recent years, interest in prognostic calculators for predicting patient health outcomes has grown with the popularity of personalized medicine. These calculators, which can inform treatment decisions, employ many different methods, each of which has advantages and disadvantages. Methods: We present a comparison of a multistate model (MSM) and a random survival forest (RSF) through a case study of prognostic predictions for patients with oropharyngeal squamous cell carcinoma. The MSM is highly structured and takes into account some aspects of the clinical context and knowledge about oropharyngeal cancer, while the RSF can be thought of as a black-box non-parametric approach. Key in this comparison are the high rate of missing values within these data and the different approaches used by the MSM and RSF to handle missingness. Results: We compare the accuracy (discrimination and calibration) of survival probabilities predicted by both approaches and use simulation studies to better understand how predictive accuracy is influenced by the approach to (1) handling missing data and (2) modeling structural/disease progression information present in the data. We conclude that both approaches have similar predictive accuracy, with a slight advantage going to the MSM. Conclusions: Although the MSM shows slightly better predictive ability than the RSF, consideration of other differences are key when selecting the best approach for addressing a specific research question. These key differences include the methods' ability to incorporate domain knowledge, and their ability to handle missing data as well as their interpretability, and ease of implementation. Ultimately, selecting the statistical method that has the most potential to aid in clinical decisions requires thoughtful consideration of the specific goals.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Survival and characteristics of 772 patients with oropharyngeal cancer and specific human papillomavirus genotypes: A Danish population-based study from 2011-2017
    Carlander, A.
    Zamani, M.
    Larsen, C. G.
    Hellelstrup, D.
    Agander, T.
    Kiss, K.
    Olsen, C.
    Baandrup, L.
    Nielsen, F. C.
    Andersen, E.
    Friborg, J. T.
    Buchwald, C. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1164 - 1164
  • [22] Survival of Australian lung cancer patients and the impact of distance from and attendance at a thoracic specialist centre: a data linkage study
    Tracey, Elizabeth
    McCaughan, Brian
    Badgery-Parker, Tim
    Young, Jane
    Armstrong, Bruce
    THORAX, 2015, 70 (02) : 152 - 160
  • [23] Elderly patients with colorectal cancer: Treatment modalities and survival in France. National data from the ThInDiT cohort study
    Doat, S.
    Thiebaut, A.
    Samson, S.
    Ricordeau, P.
    Guillemot, D.
    Mitry, E.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) : 1276 - 1283
  • [24] Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses
    Elizabeth A. Davies
    Victoria H. Coupland
    Steve Dixon
    Kefah Mokbel
    Ruth H. Jack
    BMC Cancer, 16
  • [25] Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses
    Davies, Elizabeth A.
    Coupland, Victoria H.
    Dixon, Steve
    Mokbel, Kefah
    Jack, Ruth H.
    BMC CANCER, 2016, 16
  • [26] Inequalities in treatment among patients with colon and rectal cancer: a multistate survival model using data from England National Cancer Registry 2012-2016 (vol 130, pg 88, 2024)
    Ling, Suping
    Fernandez, Miguel-Angel Luque
    Quaresma, Manuela
    Belot, Aurelien
    Rachet, Bernard
    BRITISH JOURNAL OF CANCER, 2023, 129 (12) : 2035 - 2038
  • [27] Are there social gradients in the occurrence of lung cancer and in the survival of lung cancer patients? Findings from an observational study using German claims data of Lower Saxony
    Schroeder, Sebastian
    Beller, Johannes
    Golpon, Heiko
    Geyer, Siegfried
    BMJ OPEN, 2020, 10 (09): : e036506
  • [28] Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer Evidence Based on Health Care Data from the WiZen Study
    Schoffer, Olaf
    Wimberger, Pauline
    Gerken, Michael
    Bierbaum, Veronika
    Bobeth, Christoph
    Roessler, Martin
    Droege, Patrik
    Ruhnke, Thomas
    Guenster, Christian
    Kleihues-van Tol, Kees
    Link, Theresa
    Scharl, Anton
    Inwald, Elisabeth C.
    Kast, Karin
    Papathemelis, Thomas
    Ortmann, Olaf
    Klinkhammer-Schalke, Monika
    Schmitt, Jochen
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (02) : 153 - 163
  • [29] The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study
    van Soest, Robert
    de Morree, Ellen
    Shen, Liji
    Tannock, Ian
    Eisenberger, Mario A.
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [30] Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer
    Monk, Bradley J.
    Pandite, Lini N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) : 4845 - 4845